Kunqian Ji

Dr. Kunqian Ji


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
YLYan Lin
Yan Lin
DWDongdong Wang
Dongdong Wang
BLBusu Li
Busu Li
JWJiayin Wang
Jiayin Wang
LXLing Xu
Ling Xu
YZYuying Zhao
Yuying Zhao
Autosomal dominant optic atrophy plus (ADOA+) is characterized by primary optic nerve atrophy accompanied by a spectrum of degenerative neurological symptoms. Despite ongoing research, no effective treatments are currently available for this condition. Our study provided evidence for the pathogenicity of an unreported c.1780T>C variant in the OPA1 gene through patient-derived skin fibroblasts and an engineered HEK293T cell line with OPA1 downregulation. We demonstrate that OPA1 insufficiency promoted mitochondrial fragmentation and increased DRP1 expression, disrupting mitochondrial dynamics. Consequently, this disruption enhanced mitophagy and caused mitochondrial dysfunction, contributing to the ADOA+ phenotype. Notably, the Drp1 inhibitor, mitochondrial division inhibitor-1 (Mdivi-1), effectively mitigated the adverse effects of OPA1 impairment. These effects included reduced Drp1 phosphorylation, decreased mitochondrial fragmentation, and balanced mitophagy. Thus, we propose that intervening in DRP1 with Mdivi-1 could correct mitochondrial abnormalities, offering a promising therapeutic approach for managing ADOA+.

12 December 2013 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
KLKaiming Liu
Kaiming Liu
HZHui Zhao
Hui Zhao
KJKunqian Ji
Kunqian Ji
CYChuanzhu Yan
Chuanzhu Yan

9 October 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JLJia-Li Lu
Jia-Li Lu
YDYichen Dai
Yichen Dai
KJKunqian Ji
Kunqian Ji
GPGui-Xin Peng
Gui-Xin Peng
HLHong Li
Hong Li
XZXiao-Long Zhou
Xiao-Long Zhou
Escherichia coli MnmE and MnmG form a complex (EcMnmEG), generating transfer RNA (tRNA) 5-carboxymethylaminomethyluridine (cmnm5U) modification. Both cmnm5U and equivalent 5-taurinomethyluridine (τm5U, catalyzed by homologous GTPBP3 and MTO1) are found at U34 in several human mitochondrial tRNAs (hmtRNAs). Certain mitochondrial DNA (mtDNA) mutations, including m.3243A > G in tRNALeu(UUR) and m.8344A > G in tRNALys, cause genetic diseases, partially due to τm5U hypomodification. However, whether other mtDNA variants in different tRNAs cause a defect in τm5U biogenesis remains unknown. Here, we purified naturally assembled EcMnmEG from E. coli. Notably, EcMnmEG was able to incorporate both cmnm5U and τm5U into hmtRNATrp (encoded by MT-TW), providing a valuable basis for directly monitoring the effects of mtDNA mutations on U34 modification. In vitro, several clinical hmtRNATrp pathogenic mutations caused U34 hypomodification. A patient harboring an m.5541C > T mutation exhibited hmtRNATrp τm5U hypomodification. Moreover, using mtDNA base editing, we constructed two cell lines carrying m.5532G > A or m.5545C > T mutations, both of which exhibited hmtRNATrp τm5U hypomodification. Taurine supplementation improved mitochondrial translation in patient cells. Our findings describe the third hmtRNA species with mutation-related τm5U-hypomodification and provide new insights into the pathogenesis and intervention strategy for hmtRNATrp-related genetic diseases.

25 March 2022 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
JLJingwei Lyu
Jingwei Lyu
YZYuying Zhao
Yuying Zhao
NZNa Zhang
Na Zhang
XXXuebi Xu
Xuebi Xu
RZRui Zheng
Rui Zheng
KJKunqian Ji
Kunqian Ji

23 May 2023 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
YZYuying Zhao
Yuying Zhao
XXXuebi Xu
Xuebi Xu
XMXiaotian Ma
Xiaotian Ma
YSYuan Sun
Yuan Sun
KJKunqian Ji
Kunqian Ji
Objective: To explore the clinical characteristics of mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (MELAS) caused by mitochondrial DNA‐encoded complex I subunit (mt‐ND) variants.Methods: In this retrospective study, the clinical, myopathological and brain MRI features of patients with MELAS caused by mt‐ND variants (MELAS‐mtND) were collected and compared with those of MELAS patients carrying the m.3243A > G variant (MELAS‐A3243G).Result: A total of 18 MELAS‐mtND patients (female: 7; median age: 24.5 years) represented 15.9% (n = 113) of all patients with MELAS caused by mtDNA variants in our neuromuscular center from January 2012 to June 2022. In this MELAS‐mtND cohort, the two most common variants were m.10191 T > C (4/18, 22.2%) and m.13513 G > A (3/18, 16.7%). The most frequent symptoms were seizures (14/18, 77.8%) and muscle weakness (11/18, 61.1%). Compared with 87 MELAS‐A3243G patients, MELAS‐mtND patients were significantly more likely to have a variant that was absent in blood cells (40% vs. 1.4%). Furthermore, MELAS‐mtND patients had a significantly lower MDC score (7.8 ± 2.7 vs. 9.8 ± 1.9); less hearing loss (27.8% vs. 54.0%), diabetes (11.1% vs. 37.9%), and migraine (33.3% vs. 62.1%); less short stature (males ≤ 165 cm; females ≤ 155 cm; 23.1% vs. 60.8%) and higher body mass index (20.4 ± 2.5 vs. 17.8 ± 2.7). MELAS‐mtND patients had significantly more normal muscle pathology (31.3% vs. 4.1%) and fewer RRFs/RBFs (62.5% vs. 91.9%), COX‐deficient fibers/blue fibers (25.0% vs. 85.1%) and SSVs (50.0% vs. 81.1%). Moreover, brain MRI evaluated at the first stroke‐like episode showed significantly more small cortical lesions in MELAS‐mtND patients (66.7% vs. 12.2%).Interpretation: Our results suggested that MELAS‐mtND patients have distinct clinical, myopathological and brain MRI features compared with MELAS‐A3243G patients.

21 August 2023 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
YZYing Zhao
Ying Zhao
YLYan Lin
Yan Lin
BWBin Wang
Bin Wang
FLFuchen Liu
Fuchen Liu
DZDandan Zhao
Dandan Zhao
KJKunqian Ji
Kunqian Ji